Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Current Investments (2016 - 2025)

Tg Therapeutics has reported Cash & Current Investments over the past 10 years, most recently at $142.0 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $142.0 million for Q4 2025, up 7.98% from a year ago — trailing twelve months through Dec 2025 was $142.0 million (up 7.98% YoY), and the annual figure for FY2025 was $142.0 million, up 7.98%.
  • Cash & Current Investments for Q4 2025 was $142.0 million at Tg Therapeutics, up from $59.3 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for TGTX hit a ceiling of $523.8 million in Q1 2021 and a floor of $59.3 million in Q3 2025.
  • Median Cash & Current Investments over the past 5 years was $217.4 million (2023), compared with a mean of $238.3 million.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 568.73% in 2021 and later crashed 82.62% in 2025.
  • Tg Therapeutics' Cash & Current Investments stood at $314.8 million in 2021, then crashed by 48.64% to $161.7 million in 2022, then surged by 34.53% to $217.5 million in 2023, then crashed by 39.55% to $131.5 million in 2024, then grew by 7.98% to $142.0 million in 2025.
  • The last three reported values for Cash & Current Investments were $142.0 million (Q4 2025), $59.3 million (Q3 2025), and $251.9 million (Q2 2025) per Business Quant data.